2019
LBA79 Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
Herbst R, Lopes G, Kowalski D, Nishio M, Wu Y, de Castro G, Baas P, Kim D, Gubens M, Cristescu R, Aurora-Garg D, Albright A, Ayers M, Loboda A, Lunceford J, Kobie J, Lubiniecki G, Pietanza M, Piperdi B, Mok T. LBA79 Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. Annals Of Oncology 2019, 30: v916-v917. DOI: 10.1093/annonc/mdz394.077.Peer-Reviewed Original ResearchBristol-Myers SquibbTissue TMBGenentech/RocheSubsidiary of MerckDohme Corp.KEYNOTE-010KEYNOTE-042PD-L1Merck SeronoBoehringer IngelheimMerck SharpAdvanced NSCLCClinical outcomesEli LillyOno PharmaceuticalCox proportional hazards modelPositive advanced NSCLCResults Baseline characteristicsSubset of ptsOpen-label trialTotal study populationProportional hazards modelRoche/GenentechMultiple tumor typesWhole-exome sequencing
2009
Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy
Otterson G, O’Connor P, Lin M, Herbst R. Safety of bevacizumab (B) and erlotinib (E) therapy in patients (pts) with treated brain metastases (mets) in the phase III, placebo (P)-controlled, randomized BeTa trial for pts with advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. Journal Of Clinical Oncology 2009, 27: e19025-e19025. DOI: 10.1200/jco.2009.27.15_suppl.e19025.Peer-Reviewed Original ResearchNon-small cell lung cancerBrain metsBrain metastasesAdverse eventsTreatment durationAdvanced non-small cell lung cancerAdvanced stage non-small cell lung cancerStage non-small cell lung cancerEpidermal growth factor receptor-targeted therapyLung StudyNervous system adverse eventsStandard first-line chemotherapyWhole-brain radiation therapySafety of bevacizumabSubset of ptsCarboplatin/paclitaxelFirst-line chemotherapyMedian treatment durationAcceptable safety profileAdvanced NSCLC patientsBrain radiation therapyFirst-line treatmentNew safety signalsSubset of patientsReceptor-targeted therapy